Immune checkpoint inhibitors for extensive-stage small-cell lung cancer: a network meta-analysis and cost-effectiveness analysis
Benmelstobart and anlotinib plus chemotherapy demonstrated superior efficacy regarding OS, PFS, and ORR, while tislelizumab plus chemotherapy provided the most favorable safety profile among the evaluated ICI-based therapies. And none of the evaluated ICI-based regimens were cost-effective at the conventional WTP threshold. However, tislelizumab plus chemotherapy was the most cost-effective as the WTP threshold increased.
Authors
- Yuxuan Zhu (ORCID: https://orcid.org/0000-0002-5234-8506)
- Z. D. Liu (ORCID: https://orcid.org/0000-0001-5862-6063)
- Qi Tang (ORCID: https://orcid.org/0000-0001-9614-1075)
- Silu Xu (ORCID: https://orcid.org/0000-0002-3318-4219)
- Nan Wu (ORCID: https://orcid.org/0000-0002-9429-2889)
- J. Zhang
- Guoren Zhou (ORCID: https://orcid.org/0000-0001-5344-8480)
- Ji‐Fu Wei (ORCID: https://orcid.org/0000-0001-6412-3251)
- Xin Liu (ORCID: https://orcid.org/0009-0006-2118-3549)
- Yifei Zhu (ORCID: https://orcid.org/0000-0001-5393-0445)
- Yuhao Sun (ORCID: https://orcid.org/0000-0001-6640-6888)
- Jiayu Wen
Institutions
- China Pharmaceutical University (CN)
- Jiangsu Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.3389/fimmu.2025.1662438
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00